Vimarsana
Biggest News Aggregation in the World

Both Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Both Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Both Phase Today - Breaking & Trending Today

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials - Vimarsana News

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

An Independent Data and Safety Monitoring Board Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials...

Foreign Direct Investment Screening in the Netherlands: New Regime In Force | Jones Day - Vimarsana News

Foreign Direct Investment Screening in the Netherlands: New Regime In Force | Jones Day

In Short - The Development: On 1 June 2023, the Security Screening of Investment, Mergers and Acquisitions Act (Wet Veiligheidstoets investeringen, fusies en overnames)...

Salt Lake City airport unveils 12 new concessions as its growth continues - Vimarsana News

Salt Lake City airport unveils 12 new concessions as its growth continues

Salt Lake City International Airport officials announced six more restaurants and another six retail stores that will open as a part of the third phase of construction at the airport.

Source: ksl.com
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022 - Vimarsana News

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing, manufacturing and...

Swedish Orphan Biovitrum : 22 March – Phase 3 study results SEL-212 - Vimarsana News

Swedish Orphan Biovitrum : 22 March – Phase 3 study results SEL-212

Both Phase 3 Studies and both tested doses met primary efficacy endpoints, achieving a statistically significant response rate with SEL-212 versus placebo ... | March 27, 2023